Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system

Hazel Clothier; Laine Hosking; Nigel Crawford; Melissa Russell; Mee Lee Easton; Julie-Ann Quinn; James Peter Buttery

doi:10.1007/s40264-014-0248-6

Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system

Hazel Clothier
, Laine Hosking
, Nigel Crawford
, Melissa Russell
, Mee Lee Easton
, Julie-Ann Quinn
, James Peter Buttery

Paediatrics Monash Health

Research output: Contribution to journal › Article › Research › peer-review

16 Citations (Scopus)

Abstract

Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.

Original language	English
Pages (from-to)	79 - 86
Number of pages	8
Journal	Drug Safety
Volume	38
Issue number	1
DOIs	https://doi.org/10.1007/s40264-014-0248-6
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s40264-014-0248-6

Cite this

@article{38c9d047f92d49239870b50d318f66da,

title = "Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system",

abstract = "Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.",

author = "Hazel Clothier and Laine Hosking and Nigel Crawford and Melissa Russell and Easton, \{Mee Lee\} and Julie-Ann Quinn and Buttery, \{James Peter\}",

year = "2015",

doi = "10.1007/s40264-014-0248-6",

language = "English",

volume = "38",

pages = "79 -- 86",

journal = "Drug Safety",

issn = "0114-5916",

publisher = "Springer - Adis",

number = "1",

}

TY - JOUR

T1 - Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system

AU - Clothier, Hazel

AU - Hosking, Laine

AU - Crawford, Nigel

AU - Russell, Melissa

AU - Easton, Mee Lee

AU - Quinn, Julie-Ann

AU - Buttery, James Peter

PY - 2015

Y1 - 2015

N2 - Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.

AB - Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.

UR - http://link.springer.com/article/10.1007%2Fs40264-014-0248-6

U2 - 10.1007/s40264-014-0248-6

DO - 10.1007/s40264-014-0248-6

M3 - Article

SN - 0114-5916

VL - 38

SP - 79

EP - 86

JO - Drug Safety

JF - Drug Safety

IS - 1

ER -

Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system

Abstract

UN SDGs

Access to Document

Other files and links

Cite this